Bioavailability of Aciclovir After Oral Administration of Aciclovir and Its Prodrug Valaciclovir to Patients with Leukopenia After Chemotherapy

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1999 Dec 22

PMID 10602752

Citations 19

Authors

H Steingrimsdottir

A Gruber

C Palm

G Grimfors

M Kalin

S Eksborg

Affiliations

Soon will be listed here.

Abstract

The median bioavailabilities of aciclovir after administration of aciclovir and its prodrug valaciclovir were 21.5 and 70.1%, respectively, in 12 patients with malignant hematological diseases with leukopenia after chemotherapy. The interindividual variations of the bioavailability were 48.5 and 21.0% after administration of aciclovir and valaciclovir, respectively. Neither the bioavailability nor the interindividual variation of area under the concentration-time curve of oral aciclovir or valaciclovir differed from that reported in healthy volunteers.

Citing Articles

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir.

Qureshi A, Ouattara L, El-Sayed N, Verma A, Doncel G, Choudhary M Molecules. 2022; 27(14).

PMID: 35889320 PMC: 9316519. DOI: 10.3390/molecules27144447.

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes....

Henze L, Buhl C, Sandherr M, Cornely O, Heinz W, Khodamoradi Y Ann Hematol. 2022; 101(3):491-511.

PMID: 34994811 PMC: 8810475. DOI: 10.1007/s00277-021-04746-y.

Enzyme Models-From Catalysis to Prodrugs.

Breijyeh Z, Karaman R Molecules. 2021; 26(11).

PMID: 34071328 PMC: 8198240. DOI: 10.3390/molecules26113248.

Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study.

Shin S, Kim T, Lee D, Chung S, Lee J, Kim D AAPS J. 2020; 22(2):27.

PMID: 31938935 DOI: 10.1208/s12248-019-0382-2.

Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers.

Rouphael N, Hurwitz S, Hart M, Beck A, Anderson E, Deye G Antimicrob Agents Chemother. 2019; 63(9).

PMID: 31285228 PMC: 6709474. DOI: 10.1128/AAC.00717-19.

References

Seaber E, On N, Wootton R, Rolan P, Posner J . Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995; 39(12):2759-64. PMC: 163025. DOI: 10.1128/AAC.39.12.2759. View

Wang L, Schultz M, Weller S, Smiley M, Blum M . Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob Agents Chemother. 1996; 40(1):80-5. PMC: 163061. DOI: 10.1128/AAC.40.1.80. View

Svensson J, Barkholt L, Sawe J . Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997; 690(1-2):363-6. DOI: 10.1016/s0378-4347(96)00424-0. View

Johansson J, Ekman T . Gastro-intestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant. 1997; 19(9):921-5. DOI: 10.1038/sj.bmt.1700765. View

Al-Yamani M, Al-Khamis K, El-Sayed Y, Bawazir S, Al-Rashood K, Gouda M . Comparative bioavailability of two tablet formulations of acyclovir in healthy volunteers. Int J Clin Pharmacol Ther. 1998; 36(4):222-6. View

Boxenbaum H, RIEGELMAN S, Elashoff R . Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974; 2(2):123-48. DOI: 10.1007/BF01061504. View

Blum M, Liao S, de Miranda P . Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982; 73(1A):186-92. DOI: 10.1016/0002-9343(82)90088-2. View

de Miranda P, Blum M . Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983; 12 Suppl B:29-37. DOI: 10.1093/jac/12.suppl_b.29. View

Dunne A . JANA: a new iterative polyexponential curve stripping program. Comput Methods Programs Biomed. 1985; 20(3):269-75. DOI: 10.1016/0169-2607(85)90085-9. View

10.

Johnson E, MacGowan A, Potter M, Stockley R, White L, Slade R . Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother. 1990; 25(5):837-42. DOI: 10.1093/jac/25.5.837. View

11.

Endrenyi L, Fritsch S, Yan W . Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol. 1991; 29(10):394-9. View

12.

Gubbins P, Bertch K . Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1991; 21(6):431-47. DOI: 10.2165/00003088-199121060-00004. View

13.

Weller S, Blum M, Doucette M, Burnette T, Cederberg D, de Miranda P . Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993; 54(6):595-605. DOI: 10.1038/clpt.1993.196. View

14.

Jacobson M, Gallant J, Wang L, Coakley D, Weller S, Gary D . Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 1994; 38(7):1534-40. PMC: 284589. DOI: 10.1128/AAC.38.7.1534. View

15.

Vergin H, Kikuta C, Mascher H, Metz R . Pharmacokinetics and bioavailability of different formulations of aciclovir. Arzneimittelforschung. 1995; 45(4):508-15. View